Published in PLoS One on December 30, 2016
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov (2011) 5.79
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab (2009) 3.16
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell (2015) 3.03
Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist (2004) 2.72
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell (2015) 2.60
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol (2005) 2.51
The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab (2014) 2.06
T cell metabolism drives immunity. J Exp Med (2015) 2.06
Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol (2008) 1.89
Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci Signal (2015) 1.56
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol (2009) 1.54
GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol (2011) 1.50
SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res (2012) 1.46
A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum Pathol (2012) 1.42
The transport of glutamine into mammalian cells. Front Biosci (2007) 1.25
ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. Br J Cancer (2014) 1.22
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol (2015) 1.14
Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am J Physiol Gastrointest Liver Physiol (2002) 1.11
ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene (2015) 1.06
GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am J Clin Pathol (2003) 0.98
Expression characteristics of hypoxia-inducible factor-1α and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepat Mon (2011) 0.91
CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma. J Exp Clin Cancer Res (2015) 0.90
Upregulated SLC1A5 promotes cell growth and survival in colorectal cancer. Int J Clin Exp Pathol (2014) 0.89
An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. J Hepatol (2012) 0.88
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 0.88
Nutrient Competition: A New Axis of Tumor Immunosuppression. Cell (2015) 0.86
Overexpression of GLUT1 in colorectal cancer is independently associated with poor prognosis. Int J Biol Markers (2011) 0.84
Lactate promotes glutamine uptake and metabolism in oxidative cancer cells. Cell Cycle (2016) 0.80
High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma. Sci Rep (2015) 0.78
miR-132 mediates a metabolic shift in prostate cancer cells by targeting Glut1. FEBS Open Bio (2016) 0.78